Request for Application - Evolutionary Therapy (Trials) - Deadline LOI 1 March 2021
|Thread Post Created on Thu, December 3, 2020 10:21 AM|
Opportunity open to applicants from all countries. Please read the eligibility criteria & instructions carefully before applying: https://www.anticancerfund.org/en/evolutionary-therapy
This Request for Application (RFA) seeks to increase clinical trial activity of evolutionarily informed therapeutic strategies aiming at improving survival outcomes of cancer patients.
Knowledge about tumour evolutionary dynamics has been growing rapidly. However, there has been a limited translation of that knowledge into therapeutic trials. The most clinically advanced strategy is adaptive therapy. Adaptive therapy is a treatment strategy attempting to prolong response to treatment by delaying the emergence of resistance. The goal of adaptive therapy is to maintain a controllable stable tumour burden by allowing a significant population of treatment-sensitive cells to survive. The main principle of the intervention is to control the tumour and prolong survival by allowing on/off treatment periods based on a valid marker.
This RFA will accept clinical trials on adaptive therapy and any other evolutionarily informed strategy, as long as they meet all criteria (see eligibility criteria).
We encourage investigators working on evolutionarily informed strategies (including adaptive therapy) to apply for funding for their clinical trial evaluating such approach in cancer patients.
For further information on what is seen as evolutionarily informed strategies and adaptive therapy, we would like to refer applicants to a recent article by Gatenby & Brown (Gatenby RA, Brown JS. Integrating evolutionary dynamics into cancer therapy. Nat Rev Clin Oncol 2020; 17: 675–86).
Please contact firstname.lastname@example.org for any questions related to the RFA and to check eligibility of their proposal in case of doubt.